Werewolf Therapeutics/ US95075A1079 /
| 11/14/2024 6:33:33 PM | Chg. -0.11 | Volume | Bid- | Ask6:37:49 PM | High | Low |
|---|---|---|---|---|---|---|
| 1.96USD | -5.10% | 4,555 Turnover: 9,068.22 |
-Bid Size: - | 1.96Ask Size: 200 | 2.03 | 1.93 |
GlobeNewswire
8/8
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
6/25
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical ...
GlobeNewswire
6/1
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monothera...
GlobeNewswire
5/30
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
GlobeNewswire
5/23
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monothera...
GlobeNewswire
5/3
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
4/24
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 Amer...
GlobeNewswire
4/23
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Pot...
GlobeNewswire
4/5
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammat...
GlobeNewswire
4/4
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform...
GlobeNewswire
3/7
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Busin...
GlobeNewswire
3/6
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
GlobeNewswire
3/5
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
GlobeNewswire
1/8
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
GlobeNewswire
11/14/2023
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire
11/3/2023
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establish...
GlobeNewswire
10/31/2023
Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of C...
GlobeNewswire
9/27/2023
Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s ...
GlobeNewswire
9/11/2023
Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124
GlobeNewswire
3/24/2022
Werewolf Therapeutics Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides ...
GlobeNewswire
3/16/2022
Werewolf Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy of WTX-12...
GlobeNewswire
3/15/2022
Werewolf Therapeutics Announces Upcoming Presentations at AACR 2022 Annual Meeting
